Clinical Trial 23779

• Overview

  Study Title:

  A Phase 1/2a Study to Assess Safety, Tolerability, and Efficacy of [212Pb]Pb-DOTAM-MAM279 in Patients with Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

• Treatments

  Therapies:

  DLL3- Targeted radiopharmaceuticals; Diagnostic Spect Radioligand; Radiopharmaceutical; Therapeutic radioligand therapy

  Medications:

  [203Pb]Pb-DOTAM-MAM279 (); [212Pb]Pb-DOTAM-MAM279 ()

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.